Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 known ✓ | P00519 | 17/20 | 0.71 |
| ▸ | PDGFRA known ✓ | P16234 | 10/20 | 0.71 |
| ▸ | PDGFRB known ✓ | P09619 | 9/20 | 0.71 |
| ▸ | BCR known ✓ | P11274 | 8/20 | 0.71 |
| ▸ | KIT known ✓ | P10721 | 7/20 | 0.71 |
| ▸ | LCK known ✓ | P06239 | 4/20 | 0.71 |
| ▸ | FLT3 known ✓ | P36888 | 4/20 | 0.71 |
| ▸ | CACNA1F known ✓ | O60840 | 1/20 | 0.71 |
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.71 |
| ▸ | CSF1R known ✓ | P07333 | 1/20 | 0.71 |
| ▸ | RET known ✓ | P07949 | 1/20 | 0.71 |
| ▸ | SRC known ✓ | P12931 | 1/20 | 0.71 |
| ▸ | TACR1 known ✓ | P25103 | 1/20 | 0.71 |
| ▸ | OPRK1 known ✓ | P41145 | 1/20 | 0.71 |
| ▸ | CACNA1D known ✓ | Q01668 | 1/20 | 0.71 |
| ▸ | PDE4D known ✓ | Q08499 | 1/20 | 0.71 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.71 |
| ▸ | CACNA1S known ✓ | Q13698 | 1/20 | 0.71 |
| ▸ | CACNA1C known ✓ | Q13936 | 1/20 | 0.71 |
| ▸ | NTRK3 known ✓ | Q16288 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1754053 | 0.99 | ABL1 (0.70) | ABL1PDGFRAPDGFRBBCRKIT | |
| SCHEMBL1005305 | 0.99 | ABL1 (0.72) | ABL1PDGFRAPDGFRBBCRKIT | |
| SCHEMBL4710149 | 0.91 | ABL1 (0.70) | ABL1PDGFRAPDGFRBBCRKIT | |
| SCHEMBL1653905 | 0.90 | ABL1 (0.76) | ABL1PDGFRAPDGFRBBCRKIT | |
| SCHEMBL3362592 | 0.88 | ABL1 (0.58) | ABL1PDGFRAPDGFRBBCRKIT | |
| SCHEMBL1566537 | 0.86 | ABL1 (0.74) | ABL1PDGFRAPDGFRBBCRKIT | |
| SCHEMBL1653904 | 0.86 | PDGFRA (0.71) | ABL1PDGFRAPDGFRBBCRKIT | |
| SCHEMBL4713847 | 0.86 | ABL1 (0.56) | ABL1PDGFRAPDGFRBBCRKIT | |
| SCHEMBL21207742 | 0.86 | ABL1 (0.75) | ABL1PDGFRAPDGFRBBCRKIT | |
| SCHEMBL1654099 | 0.85 | ABL1 (0.74) | ABL1PDGFRAPDGFRBBCRKIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2543665-A2 | Crystalline forms of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide free base | Novartis AG (CH) | 2013-01-09 | — | — | EP | disclosed |
| EP-2530081-A2 | Nilotinib HCI crystalline forms | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2012-12-05 | — | — | EP | disclosed |
| EP-1912973-A2 | CRYSTALLINE FORMS OF 4-METHYL-N-[3-(4-METHYL-IMIDAZOL-1-YL)-5-TRIFLUOROMETHYL-PHENYL]3-(4-PYRIDIN-3-YL-PYRIMIDIN-2-YLAMINO)-BENZAMIDE | Novartis AG (CH) | 2008-04-23 | — | — | EP | disclosed |
| WO-2007015870-A2 | CRYSTALLINE FORMS OF 4-METHYL-N-[3-(4-METHYL-IMIDAZOL-1-YL)-5-TRIFLUOROMETHYL-PHENYL]-3-(4-PYRIDIN-3-YL-PYRIMIDIN-2-YLAMINO)-BENZAMIDE | NOVARTIS AG (CH) | 2007-02-08 | — | — | WO | disclosed |